Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of mRNA-1325 Zika Vaccine in Healthy Adults
NCT03014089Phase 1Completed
- Sponsor
- Moderna Inc
- Start
- Dec 2016
- Primary completion
- Jul 2019
- Modality
- Vaccines & Immunotherapeutics, Lipid-based Nanoparticles, mRNA Therapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in Zika virus infection comparing mRNA-1325 with Placebo (2 arms). Primary endpoints: Number of Participants With Solicited Adverse Events- Vaccination 1, Number of Participants With Solicited Adverse Events: Vaccination 2 and 3 more. Started Dec 2016; status: completed.
02
Drugs
mRNA-1325
03
Conditions
Zika virus infection
Beyond the preview
Go deeper on NCT03014089.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03014089.